Smart-Money SignalNeutral · 47/100— Insiders are net sellers over 90 days (-$85K, 3 sales vs 4 buys)
Revenue$2.5B
Net Income$319.5M
EPS$2.15
Market Cap$29.6B
Price Performance
Historical data including institutional events
Company Profile
C
Christopher A. Viehbacher
CEO & Executive Director
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia ; tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
